A Phase 2 interventional study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-03-08.
Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment
The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine (decitabine) in combination with Mylotarg (gemtuzumab ozogamicin) can help to control AML or high-risk MDS. The safety of this drug combination will also be studied.
The Study Drugs:
Gemtuzumab ozogamicin is designed to attach to Sialic acid-binding Ig-like lectin 3 (CD33), a certain protein that is often found in leukemia cells, causing them to die.
Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will receive decitabine through a needle in your vein over 1 and 1/2 hours on Days 1-5 of each cycle. You will also receive gemtuzumab ozogamicin by vein over about 1 hour after you receive decitabine on Day 5 of each 4-6 week cycle.
During Cycle 1 only, if a bone marrow test done 2 weeks after you receive your first study drug treatment shows abnormal leukemia cells, you will receive another treatment with decitabine intravenously over 1 and 1/2 hours for 5 days.
Gemtuzumab may cause allergic reactions, nausea, and vomiting. To help prevent such side effects, you will receive Benadryl (diphenhydramine) and hydrocortisone. You may receive these drugs by vein, or by mouth on the days you get gemtuzumab ozogamicin during the entire study.
Study Visits:
During Cycle 1, blood (about 2 teaspoons) will be drawn at least 1 time each week for routine tests. If the doctor thinks it is necessary, you may be asked to have additional blood drawn.
During Cycle 1, after approximately 2 weeks of your first study drug administration , you will have a bone marrow aspiration to decide whether you will receive additional decitabine in Cycle 1.
During Cycles 2-3, blood (about 2 teaspoons) will be drawn for routine tests at least 2 times each month.
During Cycles 4 and beyond, blood (about 2 teaspoons) will be drawn for routine tests at least 1 time each month.
If the doctor thinks it is necessary, you may have a bone marrow aspirate every 1 to 3 months to check the status of the disease.
Length of Study:
You may receive the combination of decitabine and gemtuzumab ozogamicin for up to 6 cycles. After this, if your doctor thinks it is in your best interest, you may continue to take decitabine alone for up to 24 cycles. You will be taken off study early if the disease gets worse, you experience intolerable side effects, or your doctor thinks that it is no longer in your best interest to receive the study drug(s).
Long-term Follow-up:
Once you are off study, you will have follow up visits every month for up to 2 years. At these visits, blood (about 2 teaspoons) will be drawn for routine tests.
This is an investigational study. Gemtuzumab ozogamicin is FDA approved and commercially available for the treatment of AML that has come back after treatment in patients over the age of 65 years. Decitabine is FDA approved and commercially available for the treatment of MDS. The use of gemtuzumab ozogamicin and decitabine in combination is investigational.
Up to 100 patients will take part in this study. All will be enrolled at M. D. Anderson.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 71 is above the median of 38 across 4,247 interventional studies indexed under Leukemia.
Browse Leukemia studies →M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.
Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Decitabine 20 mg/m\^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m\^2 IV on day 5.
Drug: Decitabine · Drug: Gemtuzumab Ozogamicin
20 mg/m\^2 IV over an hour and half daily for 5 days.
Also known as: Dacogen
3 mg/m\^2 IV on day 5.
Also known as: Gemtuzumab, Mylotarg
Number of Participants With Complete Response (CR)
Complete Response (CR) was defined as normalization of peripheral blood and bone marrow with \</= 5% blasts, a peripheral anc \>/= 1 \* 10\^9 /l, and a platelet count of \>/= 100 \& 10\^9 /l. Evaluation after each treatment course (5-6 weeks) up to 6 cycles.
Time frame: Up to 36 weeks
Recruitment Period: 2/19/2008 through 5/12/2009. All participants recruited at UT MD Anderson Cancer Center.
| Milestone | Decitabine + Gemtuzumab Ozogamicin |
|---|---|
| Started | 71 |
| Completed | 71 |
| Not completed | 0 |
Complete Response (CR) was defined as normalization of peripheral blood and bone marrow with \</= 5% blasts, a peripheral anc \>/= 1 \* 10\^9 /l, and a platelet count of \>/= 100 \& 10\^9 /l. Evaluation after each treatment course (5-6 weeks) up to 6 cycles.
| participants | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| Number of Participants With Complete Response (CR) | 3 |
Collected over Four years, six months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine Gemtuzumab Ozogamicin | — | 15/71 (21.1%) | 44/71 (62%) |
| Event | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| DeathGeneral disorders | 15/71 |
| Event | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| Febrile NeutropeniaInfections and infestations | 24/71 |
| Infection otherInfections and infestations | 22/71 |
| HemorrhageGastrointestinal disorders | 5/71 |
| Age Continuous(years) | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| Median | 65 (26 to 65) |
| Sex: Female, Male(Participants) | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| Female | 31 |
| Male | 40 |
| Region of Enrollment(participants) | Decitabine Gemtuzumab Ozogamicin |
|---|---|
| United States | 71 |
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
M.D. Anderson Cancer Center